Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668304 · ClinicalTrials.gov registry record · Phase 4
Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT00668304 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 192 participants.
The verdict
NCT00668304, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
Interventions
- DRUG Avelox (Moxifloxacin, BAY12-8039)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668304
The ClinicalTrials.gov registry entry for NCT00668304 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avelox (Moxifloxacin, BAY12-8039) is the first listed.
NCT00668304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668304 about?
NCT00668304 is a clinical study titled "Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox". This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
What is the current status of trial NCT00668304?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2004-06. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00668304?
The interventions under investigation include: Avelox (Moxifloxacin, BAY12-8039) (DRUG).
Who is sponsoring clinical trial NCT00668304?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.